Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
ACTAVIS Dec-18 |
DIVIS LABORATORIES/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 14,156 | - | |
Low | Rs | 1,115 | 9,496 | - | |
Sales per share (Unadj.) | Rs | 186.3 | 3,472.6 | - | |
Earnings per share (Unadj.) | Rs | 51.0 | -1,118.5 | - | |
Cash flow per share (Unadj.) | Rs | 57.3 | 365.9 | - | |
Dividends per share (Unadj.) | Rs | 16.00 | 0 | - | |
Dividend yield (eoy) | % | 1.2 | 0 | - | |
Book value per share (Unadj.) | Rs | 261.8 | 14,322.7 | - | |
Shares outstanding (eoy) | m | 265.47 | 332.60 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 7.4 | 3.4 | 217.0% | |
Avg P/E ratio | x | 27.0 | -10.6 | -255.6% | |
P/CF ratio (eoy) | x | 24.0 | 32.3 | 74.3% | |
Price / Book Value ratio | x | 5.3 | 0.8 | 637.1% | |
Dividend payout | % | 31.4 | 0 | - | |
Avg Mkt Cap | Rs m | 365,592 | 3,933,432 | 9.3% | |
No. of employees | `000 | 11.8 | 16.9 | 70.1% | |
Total wages/salary | Rs m | 5,423 | 0 | - | |
Avg. sales/employee | Rs Th | 4,175.1 | 68,341.8 | 6.1% | |
Avg. wages/employee | Rs Th | 457.7 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,141.8 | -22,012.9 | -5.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 1,154,977 | 4.3% | |
Other income | Rs m | 1,556 | 22,087 | 7.0% | |
Total revenues | Rs m | 51,019 | 1,177,064 | 4.3% | |
Gross profit | Rs m | 18,718 | 30,266 | 61.8% | |
Depreciation | Rs m | 1,689 | 493,728 | 0.3% | |
Interest | Rs m | 35 | 66,649 | 0.1% | |
Profit before tax | Rs m | 18,551 | -508,023 | -3.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 129,566 | 0.0% | |
Tax | Rs m | 5,023 | -6,438 | -78.0% | |
Profit after tax | Rs m | 13,527 | -372,019 | -3.6% | |
Gross profit margin | % | 37.8 | 2.6 | 1,444.1% | |
Effective tax rate | % | 27.1 | 1.3 | 2,136.8% | |
Net profit margin | % | 27.3 | -32.2 | -84.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 473,711 | 9.8% | |
Current liabilities | Rs m | 8,468 | 419,060 | 2.0% | |
Net working cap to sales | % | 76.9 | 4.7 | 1,625.0% | |
Current ratio | x | 5.5 | 1.1 | 485.8% | |
Inventory Days | Days | 131 | 20 | 667.9% | |
Debtors Days | Days | 86 | 66 | 129.5% | |
Net fixed assets | Rs m | 25,797 | 130,737 | 19.7% | |
Share capital | Rs m | 531 | 0 | - | |
Net worth | Rs m | 69,493 | 4,763,740 | 1.5% | |
Long term debt | Rs m | 0 | 1,677,486 | 0.0% | |
Total assets | Rs m | 80,383 | 7,446,810 | 1.1% | |
Interest coverage | x | 531.0 | -6.6 | -8,018.6% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.2 | 396.7% | |
Return on assets | % | 16.9 | -4.1 | -411.5% | |
Return on equity | % | 19.5 | -7.8 | -249.3% | |
Return on capital | % | 26.7 | -4.8 | -552.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | 412,630 | 2.3% | |
From Investments | Rs m | -6,854 | 226,686 | -3.0% | |
From Financial Activity | Rs m | -2,459 | -708,196 | 0.3% | |
Net Cashflow | Rs m | 230 | -68,536 | -0.3% |
Compare DIVIS LABORATORIES With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare DIVIS LABORATORIES With: SANOFI INDIA FRESENIUS KABI ONCO. DR. DATSONS LABS FULFORD INDIA PIRAMAL ENTERPRISES
Asian stock markets are trading on a mixed note today as disappointing news on US consumer spending dampened sentiment ahead of a closely-watched reading on the health of the Chinese economy.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More